The Life Sciences team advised Ambys Medicines in its definitive agreement to form a strategic partnership with Takeda Pharmaceutical Company Limited (“Takeda”) to support the advancement of the Ambys platform and pipeline. Under the terms of the partnership agreement, Takeda has committed $100 million, including participation in the Series A financing. Ambys Medicines’ Series A financing was also funded by Third Rock Ventures, bringing total committed funding at launch to $140 million.
Ambys is pioneering the application of novel modalities, including cell and gene therapy and gain-of-function drug therapy, to meet the urgent need for treatments that restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today. This is in alignment with Takeda’s strategy in gastroenterology to focus on the considerable unmet need in liver through significant investment in novel chemistry and cell/gene therapy platforms.
Ambys Medicines is a biotechnology company focused on discovering and developing transformative therapies for people with advanced liver disease.